As of November 7, 2026, bioAffinity Technologies, Inc. is a publicly traded company (Nasdaq: BIAF); its largest reported holder is Bigger Michael, with 5.79% on Schedule 13G of October 1, 2025. The largest insider holding is Steven Girgenti, the chairman and a director, with 1,089,017 shares (59.8% of shares outstanding), per Form 4 of January 14, 2025 (Schedule 13G, October 1, 2025).
Is this your company?
About to sign with, pay or invest in bioAffinity Technologies, Inc.? See the free Snapshot first.
Free to see. No signup.
Is bioAffinity Technologies, Inc. a real, registered company?
- bioAffinity Technologies, Inc. files with the SEC under CIK 1712762 (its SEC filings).
- Its shares are listed under the ticker BIAF on Nasdaq (also BIAFW) (SEC company record).
- Incorporated in Delaware; business address in San Antonio, Texas, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under bioAffinity Technologies, Inc. in our court records and SEC 8-K records (as of 2026-11-07).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Bigger Michael (filed 2025-10-01).
Who are bioAffinity Technologies, Inc.'s owners and officers?
bioAffinity Technologies, Inc.: incorporated in Delaware; business address in San Antonio, Texas; industry Services-Commercial Physical & Biological Research (424B4, 2026-06-18).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2024-10-29)
- : Executive Officer (Form D, 2024-10-29)
- : Executive Officer (Form D, 2024-10-29)
- : Executive Officer (Form D, 2024-10-29)
- : Executive Officer (Form D, 2024-10-29)
- : Director (Form D, 2024-10-29)
- : Director (Form D, 2024-10-29)
- : Director (Form D, 2024-10-29)
- : Director (Form D, 2024-10-29)
- : Executive Officer, Director (Form D, 2024-10-29)
- : Director (Form D, 2024-10-29)
- : Director (Form D, 2024-10-29)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2025-10-01 | Bigger Michael | 5.79% |
Want the whole picture on bioAffinity Technologies, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on bioAffinity Technologies, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on bioAffinity Technologies, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own bioAffinity Technologies, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chairman and a director: 1,089,017 shares (59.8% of shares outstanding), 1,080,062 held directly and 8,955 indirectly (Form 4, 2025-01-14).
- , the chief executive and president: 280,359 shares (15.4% of shares outstanding) (Form 4, 2025-01-14).
- , the chief financial officer and vice president: 120,128 shares (6.6% of shares outstanding) (Form 4, 2025-01-14).
- , the secretary and executive vice president: 54,765 shares (3.0% of shares outstanding) (Form 4, 2025-01-14).
- , the chief operating officer: 41,943 shares (2.3% of shares outstanding) (Form 4, 2025-01-14).
Shares outstanding: 1,820,006 as of 2026-11-05, from the company's latest SEC cover page.
How much has bioAffinity Technologies, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2024-10-29 | $0 | $3.99M |
| Form D, 2024-08-12 | $450K | $450K |
| Form D, 2024-08-12 | $1.30M | $1.30M |
| Form D, 2024-03-20 | $2.62M | $2.62M |
Latest IPO step: bioAffinity Technologies, Inc. filed its final IPO prospectus, ticker BIAF (424B4, 2026-06-18).
IPO filings: 424B4, 2026-06-18, S-1/A, 2026-06-16, S-1, 2026-06-12, S-1, 2026-04-30, 424B4, 2025-09-30; ticker BIAF on Nasdaq Capital Market.
Keep reading
More on bioAffinity Technologies, Inc. and the records around it.
bioAffinity Technologies, Inc. elsewhere on the record
- IPO filing Jun 2026
- 5%+ stake filings Oct 2025
Companies that share a holder
- BIGGER CAPITAL FUND L P also filed stake reports on 13 other companies: ClearPoint Neuro, Inc. (Nov 2026), Dermata Therapeutics, Inc. (Nov 2026), BTC Digital Ltd. (Oct 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/bioaffinity-technologies